The evaluation of pharmacokinetic and pharmacodynamic properties of Propiverine Hydrochloride transdermal formulation

The evaluation of pharmacokinetic and pharmacodynamic properties of Propiverine Hydrochloride transdermal formulation - Pharmacokinetic and pharmacodynamic evaluation of Propiverine Hydrochloride transdermal formulation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011937

Enrollment

Registered

2013-10-01

Start date

2013-10-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

administration of propiverine hydrochloride transdermal formulation administration of propiverine hydrochloride tablet

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: to be healthy BMI:16<=, <28

Exclusion criteria

Exclusion criteria: having skin problems history of allergy

Design outcomes

Primary

Measure	Time frame
pharmacokinetic parameters and sialoschesis effect of propiverine hydrochloride	—

Countries

Japan

Contacts

Public ContactHiromitsu Imai

Oita University Hospital Clinical Pharmacology Center

imaih@oita-u.ac.jp097-586-5952

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026